Entecavir Treatment of Chronic Hepatitis D

Kabacam G., ÖNDER F. O., Yakut M., Seven G., Karatayli S. C., Karatayli E., ...More

CLINICAL INFECTIOUS DISEASES, vol.55, no.5, pp.645-650, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1093/cid/cis459
  • Journal Name: CLINICAL INFECTIOUS DISEASES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.645-650
  • Bezmialem Vakıf University Affiliated: No

Abstract

Background. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).